BIOATLA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.25 USD | +2.85% |
|
+27.95% | +32.11% |
| Mar. 27 | HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating | MT |
| Mar. 26 | Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the BioAlta (sic) [ B...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.25
USD
Average target price
11.5
USD
Spread / Average Target
+253.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.11% | 156M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- BCAB Stock
- News BioAtla, Inc.
- Transcript : BioAtla, Inc., Q3 2022 Earnings Call, Nov 03, 2022
